HOUSTON--(BUSINESS WIRE)--Feb. 4, 2015-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced that management will present at the 2015 Leerink Global Healthcare Conference at 2:40 p.m. Eastern time on Wednesday, February 11, 2015 in New York City.

The presentation will be webcast live and may be accessed from the News & Events section of the Bellicum website, at http://ir.bellicum.com/phoenix.zhtml?c=253830&p=irol-calendar. An archived version of the webcast will be available for replay for at least two weeks following the event.

About Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is using its proprietary Chemical Induction of Dimerization, or CID, technology platform to engineer and control components of the immune system in real time. The Company is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation, or HSCT, CAR T cell therapy, and dendritic cell vaccines.

Source: Bellicum Pharmaceuticals, Inc.

Investors:
Bellicum Pharmaceuticals, Inc.
Alan Musso, 832-384-1116
Chief Financial Officer
amusso@bellicum.com
or
Media:
Brad Miles, 646-513-3125
bmiles@bmccommunications.com